Category: News

Business Healthcare & Pharmaceuticals News

AstraZeneca Posts Strong Q3 Results, Citing 11% Revenue Growth in 2025 Driven by Oncology and Pipeline Success

AstraZeneca

AstraZeneca has reported strong Q3 2025 results, driven by an 11% increase in Total Revenue for the first nine months of the year. The company’s success is fueled by a 16% growth in Oncology and significant advancements in its R&D pipeline, which has seen 16 positive Phase III trials year-to-date. AstraZeneca also reiterated its full-year guidance and highlighted strategic investments, including a new $4.5 billion manufacturing facility in the US.

Business Healthcare & Pharmaceuticals News

Amgen Q3 Revenue Jumps 12% to $9.6 Billion, Driven by Strong Volume Growth

amgen

Amgen announced strong third-quarter 2025 financial results, with total revenues increasing 12% to $9.6 billion, driven by a 14% surge in product sales volume. While GAAP EPS rose 14% to $5.93, non-GAAP EPS saw a modest 1% increase due to a 31% jump in R&D spending to advance its late-stage pipeline, including the obesity drug MariTide.

Clinical Trials Healthcare & Pharmaceuticals News

Roche Announces Positive Phase III ALLEGORY Study Results for Gazyva®/Gazyvaro® in Systemic Lupus Erythematosus

Roche

Roche’s Phase III ALLEGORY study for Gazyva® (obinutuzumab) in systemic lupus erythematosus (SLE) met its primary and all key secondary endpoints. These “unprecedented” results demonstrate Gazyva’s potential to effectively control disease activity and may delay or prevent further organ damage in people with SLE.

Business Healthcare & Pharmaceuticals News

Eli Lilly to Invest $3 Billion in New Netherlands Facility to Boost Oral Medicine Production

Eli Lilly and Company

Eli Lilly has announced a $3 billion investment to build a new, state-of-the-art manufacturing facility in Katwijk, Netherlands. Located in the Leiden Bio Science Park, the advanced plant will significantly expand the company’s capacity for its growing portfolio of oral medicines, including the oral GLP-1 drug orforglipron.

Regulatory Autoimmune Diseases News

J&J Seeks U.S. FDA Approval to Expand STELARA® Use for Pediatric Ulcerative Colitis

JohnsonAndJohnson

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for STELARA® (ustekinumab) to treat children aged two years and older with moderately to severely active ulcerative colitis. The filing is supported by data from the Phase 3 UNIFI Jr clinical trial, aiming to address the significant unmet needs for this pediatric patient population.

Business Healthcare & Pharmaceuticals News

AbbVie Q3 Revenue Jumps 9.1% on Immunology Strength; Company Lifts 2025 EPS Guidance

AbbVie

AbbVie announced third-quarter 2025 net revenues of $15.776 billion, a 9.1% increase, fueled by strong growth from its immunology drugs Skyrizi and Rinvoq. GAAP diluted EPS was $0.10, impacted by IPR&D expenses, while adjusted diluted EPS was $1.86. Following the strong quarter, AbbVie raised its full-year 2025 adjusted diluted EPS guidance to $10.61 – $10.65.

Business Healthcare & Pharmaceuticals News

Gilead Announces 2025 Q3 Results; Lifts EPS Guidance as Strong HIV Sales and Other Revenue Drive

Gilead

Gilead Sciences (GILD) reported strong Q3 2025 financial results, with total revenues of $7.8 billion and non-GAAP diluted EPS jumping 22% to $2.47. The performance was driven by a 4% rise in its core business (excluding Veklury), led by its HIV franchise and $3.7 billion in Biktarvy sales. Despite a decline in Veklury and Cell Therapy revenue, the company raised its full-year 2025 diluted EPS guidance.

Business Healthcare & Pharmaceuticals News

Eli Lilly’s Q3 2025 Results Soar: Revenue Jumps 54% on Blockbuster Demand for GLP-1 Therapies; Full-Year Guidance Raised

Eli Lilly and Company

Eli Lilly reported blockbuster Q3 2025 earnings, with revenue hitting $17.6 billion on 54% year-over-year growth. The financial success was overwhelmingly driven by its incretin portfolio, particularly the high-demand GLP-1 drugs Mounjaro and Zepbound, which saw their sales soar. Following the strong performance and R&D momentum including positive Phase 3 data for the oral obesity drug orforglipron Lilly significantly raised its full-year 2025 revenue and EPS guidance.

Artificial Intelligence Business Healthcare & Pharmaceuticals News Technology

Eli Lilly Partners with NVIDIA to Build Pharma’s Most Powerful AI Supercomputer

Eli Lilly and Company

Eli Lilly is building the pharmaceutical industry’s most powerful supercomputer in collaboration with NVIDIA to create an “AI factory.” This massive system, featuring over 1,000 NVIDIA DGX B300 GPUs, will leverage decades of data to train specialized AI models, dramatically accelerating drug discovery and development while running on 100% renewable electricity.